Cucurbitacin IIa, also known as Hemslecin A, is an orally active and blood-brain barrier-permeable EGFR inhibitor, demonstrating an IC50 of 1.455 nM against human EGFR. It plays a role in inducing caspase-3-dependent apoptosis, downregulating survivin expression, and enhancing autophagy levels. This compound disrupts the actin cytoskeleton through actin aggregation, arrests the cell cycle at the G2/M phase, and provides anti-inflammatory effects by inhibiting the EGFR-MAPK signaling pathway.
- Orally active, blood-brain barrier-permeable EGFR inhibitor
- Induces caspase-3-dependent apoptosis
- Downregulates survivin expression
- Enhances autophagy levels
- Disrupts actin cytoskeleton via actin aggregation
- Arrests cell cycle at G2/M phase
- Exerts anti-inflammatory activity by inhibiting EGFR-MAPK signaling pathway
- Suitable for research in inflammation-related diseases, depression, and cancers